- Home
- NVS vs NVO Comparison
NVS vs NVO Comparison
Compare NVS & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | NVO |
|---|---|---|
| Founded | 1895 | 1923 |
| Country | Switzerland | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7B | 199.4B |
| IPO Year | 2001 | 2001 |
Fundamental Metrics
Financial Performance| Metric | NVS | NVO |
|---|---|---|
| Price | $137.36 | $43.14 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 11 |
| Target Price | ★ $144.00 | $51.00 |
| AVG Volume (30 Days) | 2.1M | ★ 9.4M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 2.16% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.30 | N/A |
| Revenue Next Year | $5.27 | $3.70 |
| P/E Ratio | $23.13 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $121.57 | $35.12 |
| 52 Week High | $170.46 | $64.16 |
Technical Indicators
Market Signals| Indicator | NVS | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 39.58 |
| Support Level | $135.55 | $43.29 |
| Resistance Level | $140.18 | $51.38 |
| Average True Range (ATR) | 2.26 | 0.90 |
| MACD | -2.36 | -0.16 |
| Stochastic Oscillator | 2.21 | 0.00 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.